BACKGROUND: Angiogenesis, the growth of new blood vessels, has a critical role in tumor growth and metastasis. The purpose of this study was to investigate the involvement of angiogenesis and angiogenic factors in the pathogenesis of renal cell carcinoma (RCC). METHODS: Formalin-fixed and paraffin-embedded tissue blocks from 70 patients with RCC were studied. The situations of tumor angiogenesis were evaluated by assessing microvessel density (MVD) through CD31 immunostaining. The expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2) and metalloproteinase-9 (MMP-9) was detected immunohistochemically. RESULTS: The value of MVD ranged from 12.0 to 93.0 with a median of 39.91 in RCC. Of the 70 RCCs, the expression of VEGF was detected in 52 (74.3%), MMP-2 in 29 (41.4%) and MMP-9 in 19 (27.1%) cases. Statistical analysis revealed significant associations of the tumor stage with MVD, and the expression of VEGF and MMP-2 in RCC. Additionally, MVD was closely related to the expression of VEGF but was not related to the expression of MMP-2 and MMP-9 in RCC. CONCLUSION: The degree of angiogenesis may be closely related to the tumor progression of RCC. The expression of VEGF may be responsible for angiogenesis in RCC, and both VEGF and MMP-2 expression may function as tumor associated angiogenic factors in RCC.
BACKGROUND: Angiogenesis, the growth of new blood vessels, has a critical role in tumor growth and metastasis. The purpose of this study was to investigate the involvement of angiogenesis and angiogenic factors in the pathogenesis of renal cell carcinoma (RCC). METHODS:Formalin-fixed and paraffin-embedded tissue blocks from 70 patients with RCC were studied. The situations of tumor angiogenesis were evaluated by assessing microvessel density (MVD) through CD31 immunostaining. The expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2) and metalloproteinase-9 (MMP-9) was detected immunohistochemically. RESULTS: The value of MVD ranged from 12.0 to 93.0 with a median of 39.91 in RCC. Of the 70 RCCs, the expression of VEGF was detected in 52 (74.3%), MMP-2 in 29 (41.4%) and MMP-9 in 19 (27.1%) cases. Statistical analysis revealed significant associations of the tumor stage with MVD, and the expression of VEGF and MMP-2 in RCC. Additionally, MVD was closely related to the expression of VEGF but was not related to the expression of MMP-2 and MMP-9 in RCC. CONCLUSION: The degree of angiogenesis may be closely related to the tumor progression of RCC. The expression of VEGF may be responsible for angiogenesis in RCC, and both VEGF and MMP-2 expression may function as tumor associated angiogenic factors in RCC.
Authors: Sabine Miebach; Stefan Grau; Vera Hummel; Peter Rieckmann; Joerg-Christian Tonn; Roland Helmut Goldbrunner Journal: J Neurooncol Date: 2006-01 Impact factor: 4.130
Authors: Sumanta Pal; Arun Azad; Shailender Bhatia; Harry Drabkin; Brian Costello; John Sarantopoulos; Ravindran Kanesvaran; Richard Lauer; Alexander Starodub; Ralph Hauke; Christopher J Sweeney; Noah M Hahn; Guru Sonpavde; Stephen Richey; Timothy Breen; Gabriel Kremmidiotis; Annabell Leske; Elizabeth Doolin; David C Bibby; Jeremy Simpson; Jose Iglesias; Thomas Hutson Journal: Clin Cancer Res Date: 2015-03-18 Impact factor: 12.531
Authors: Kaye E Brock; Gloria Gridley; Brian C-H Chiu; Abby G Ershow; Charles F Lynch; Kenneth P Cantor Journal: Br J Nutr Date: 2008-09-12 Impact factor: 3.718
Authors: J Bellmunt; J L González-Larriba; M A Climent; G López-Vivanco; L Urruticoechea; J Albanell Journal: Clin Transl Oncol Date: 2007-10 Impact factor: 3.405
Authors: T M Wright; A R Brannon; J D Gordan; A J Mikels; C Mitchell; S Chen; I Espinosa; M van de Rijn; R Pruthi; E Wallen; L Edwards; R Nusse; W K Rathmell Journal: Oncogene Date: 2009-05-18 Impact factor: 9.867